Clinical Observation Of Bujinpian In The Retreatment Of Smear-Positive Pulmonary Tuberculosis

Objective: In the study we use the retreatment of smear-positive pulmonary Tuberculosis patients as the research object.By Observing the clinical effects of Bujinpian in auxiliary treatment of the retreatment of smear-positive pulmonary Tuberculosis,to assess a new therapy adjuvanted by Traditional Chinese medicine for retreatment of smear-positive pulmonary,and the results will provide experimental bases for the Bujinpian in the retreatment of smear-positive pulmonary Tuberculosis.Methods: A total of 120 cases of retreatment smear-positive pulmonary tuberculosis for the first time were enrolled from our Hospital during september 2013 and June 2015.All subjects were randomly divided into the treatment group(60 cases)and the control group(60 cases).Patients in the treatment group were given 2(HZE+Mfx+Rfb)/6(HE+Rfb)regimen(H :isoniazid,Z:pyrazinamide,E:ethambutol,Mfx:moxifloxacin,Rfb:rifabutin),and Bujinpian,the he control group were given2(HZE+Mfx+Rfb)/6(HE+Rfb)regimen only.All patients were treated for 32 weeks.The grade of clinical symptoms and signs,the sputum smear examination、lung CT examination and the record of adverse reactions were given before and after the treatment,to observing the clinical effects of Bujinpian in auxiliary treatment of the retreatment of smear-positive pulmonary Tuberculosis.Results: 1 The grade of clinical symptoms and signs: The grade of clinical symptoms and signs at 2 months shows that the cured and markedly effective rate of the treatment group was 83.3%;the cured and markedly effective rate of the control group was 66.7%,there has a significant difference with the controled group(P<0.05)(table.1);The grade of clinical symptoms and signs at 8 months shows that the cured and markedly effective rate of the treatment group was91.7%;the cured and markedly effective rate of the control group was 76.7%,there has a significant difference with the controled group(P<0.05)(Table.1).2 The sputum negative conversion rate:the results of the sputum smear examination showde that,the sputum negative conversion rate of the treatment group was81.7%,the controled group was 60%,there has a significant difference with the controled group(P<0.05)(Table.2).The rate of negative result was about83.3%,the controled group was 80%,there was no difference with the controled group(P>0.05).3 lung CT examination: the focal Significant absorption and absorption rate of the treatment group after treatment were 61.7% and 21.7%,while the controled group were 45.0%and 28.3%,there was no difference with the controled group(P>0.05),the cavity closure rats and the Narrow rate of the treatment group after treatment were 47.8%and 30.4%,the controled group were 38.1%and 19.0%.there has no difference with the controled group(P>0.05)4 the record of adverse reactions: there were 5cases of adverse reactions in the treatment group,2 cases were impairde the liver function(3.3%),3of them has nausea,and loss of appetite(5%);there were 12 cases of adverse reactions in the controled group,7 cases were impairde the liver function,4 of them has nausea,and loss of appetite(6.7%);3 cases of leukopenia(3.3%).The incidence of adverse reaction in the treatment group(8.3%)is significantly lower than the control group(21.7%),and the differences between the two groups were significant(P<0.05).Conclusion:1 Bujinpian adjuvant therapy of the retreatment of smear-positive pulmonary Tuberculosis can significantly improve the clinical symptoms of patients during the treatment.2 Bujinpian adjuvant therapy of the retreatment of smear-positive pulmonary Tuberculosis can Increase the sputum negative conversion rate,dispose the infection sources in time and reduce the infectious patients.3 Bujinpian combined with 2(HZE+Mfx+Rfb)/6(HE+Rfb)regimen can raise the clinical cure rate of recurrent smear-positive pulmonary tuberculosis,reduce the occurrence of adverse reactions and reduce recurrence and the occurrence of drug-resistant tuberculosis.